Management system of bioequivalence studies of generic drugs of the US FDA and its enlightenment to ChinaDU Dan, YANG Yue1729-1735
Pharmacoeconomics evaluation of pegylated interferon for treating different genotypes of chronic hepatitis CCHEN Ping-yu, LIU Guo-en, XU Fei, MA Ai-xia1736-1743
Generating method and empirical study of risk response strategy in new drug research and developmentHUANG Zhe, CAO Yang, LI Hui1744-1749
Some thoughts on promoting the development of homologous industry of medicine and foodWANG Ling1755-1757
Discussion about patent protection of the invention of second medical use from industrial point of viewFENG Jin, XU Shu-wen, SHI Ying1758-1761
Consideration of clinical safety re-evaluation of toxic traditional Chinese medicineYAN Yan, WU Juan, JIAO Yue-hua, JIANG Bo, FANG Cheng, LIU Shu-min1762-1766
Technical considerations in demonstrating interchangeability of the biosimilar with the reference productHU Xiao-min, ZONG Ying, GAO Chen-yan, WANG Hai-xue, XIA Yu-ye, ZHU Jiang-bo, YUAN Bo-jun, LU Guo-cai, WANG Qing-li1767-1772
Pharmacokinetics of lyophilized cataipol powder in ratsHE Yao, XUE Qiang, CHEN Hong, XU Xiao-yu1773-1777
Research progress in consistency evaluation of the dissolution profiles of generic drugs based on CNKI databaseXUE Jing, NAN Nan, XU Ming-di, LI Ya-ping1778-1785